Godavari Drugs Reports Mixed Financial Results for Q2 2024, PAT Shows 62.87% Growth
Godavari Drugs, a microcap pharmaceutical company, has reported a flat performance in the second quarter of fiscal year 2024-2025. While the company's PAT has shown a growth of 62.87%, its Net Sales and Operating Profit have declined. Investors should carefully evaluate the company's financials before making any investment decisions.
Despite the mixed financial results, Godavari Drugs, a microcap pharmaceutical company, has recently declared its financial results for the quarter ending September 2024. The company's stock has been given a 'Sell' call by MarketsMOJO.
According to the financial report, Godavari Drugs has seen a flat performance in the second quarter of the fiscal year 2024-2025. The company's score has fallen from 10 to 3 in the last three months. However, there are some positive aspects to the company's financials.
The company's Profit After Tax (PAT) for the half-yearly period has shown a growth of 62.87% year on year, reaching Rs 2.72 crore. The company has also generated higher cash revenues from its business operations, with the Operating Cash Flow being the highest at Rs 18.41 crore annually.
On the other hand, there are some areas of concern for Godavari Drugs. The company's Net Sales for the quarter have fallen by -32.0% compared to the average of the previous four quarters. The Net Sales for the quarter were also the lowest in the last five quarters. The Operating Profit (PBDIT) and Profit Before Tax less Other Income (PBT) for the quarter were also the lowest in the last five quarters, indicating a negative trend in the near term.
Overall, Godavari Drugs has shown a mixed financial performance in the recent quarter. Investors should carefully consider all aspects before making any investment decisions.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
